Deals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
Abogen BiosciencesmRNA

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Co., Ltd. ("Abogen"), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance…

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug
AbbottBiosimilars

Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug

Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series
Arsenal BiosciencesCancer

Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series

Gentize Biopharma Raises $13.64M in Pre-Series A for Vaccine Development
FinanceGentize Biopharma

Gentize Biopharma Raises $13.64M in Pre-Series A for Vaccine Development

Illumina Partners with NVIDIA to Advance Multiomic Data Analysis
AIIllumina

Illumina Partners with NVIDIA to Advance Multiomic Data Analysis

Show More